{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"33.6","value":"0"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"48.2","value":"11.1"},{"groupId":"OG002","lowerLimit":"0.1","upperLimit":"26.0","value":"5.3"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"33.6","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or \\> 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of \\< 50% or an increase of \\< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG000","title":"Diffuse Intrinsic Pontine Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG001","title":"Ependymoma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG002","title":"High-grade Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG003","title":"Medulloblastoma"}],"paramType":"NUMBER","populationDescription":"The response population consisted of all enrolled participants receiving at least one cycle of pomalidomide if therapy was not discontinued earlier due to progressive disease (PD)","reportingStatus":"POSTED","timeFrame":"6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group","title":"Percentage of Participants With Long-term Stable Disease","type":"SECONDARY","unitOfMeasure":"percentage of participants"}